EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Market data and deal flow

How large is the US GLP-1 market—and what remains unknown?

Dose Diligence research deskSection 11 · Page 3 of 11Last updated 17 Nov 2026

Public evidence supports a large national medicine market, but this research did not identify a defensible market-size series specifically for providers with 10–100 prescribers. The national benchmarks below should frame a procurement strategy, not substitute for a bottom-up provider census.

Which spending figures are usable?

MeasureFigure and observation periodBasis and limitationSource and publication date
US GLP-1 spending across the broader categoryApproximately $128 billion in 2025 — analyst calculationASHP reported approximately 14% of $915 billion in total prescription spending. Multiplication gives $128.1 billion; rounded because the underlying share is approximate. ASHP says direct-to-consumer sales are excluded. Includes more than obesity treatment.ASHP, April 30, 2026
US GLP-1 antiobesity medicine spending$41.6 billion, 2025Reported pharmaceutical purchase expenditure; not clinic revenue or manufacturer net revenue.AJHP, April 30, 2026
Increase in US net spending attributable to GIP/GLP-1 agonists$14 billion, 2025 versus 2024Growth contribution across diabetes and obesity—not total category spending.IQVIA, April 28, 2026
Obesity-related component of that net-spending increase$9.6 billion, 2025 versus 2024Included within the $14 billion above; do not add the two figures.IQVIA, April 28, 2026
Procurement controlled by the target provider cohortNot establishedRequires provider counts, active patients, access-route mix and evidence of who controls expenditure.Research gap as of November 17, 2026

The approximately $128 billion calculation and the $41.6 billion obesity figure are overlapping measures, not additive market segments. IQVIA’s net-spending growth also uses a different economic basis from purchase expenditure. Its report explicitly distinguishes list-price and net-price measures. IQVIA methodology and findings

What do the latest manufacturer results show?

US commercial indicatorQ3 2026 observationComparisonSource
Mounjaro revenueApproximately $5.0 billion41% growth versus Q3 2025Lilly, October 29, 2026
Zepbound revenueApproximately $5.3 billion48% growth versus Q3 2025Lilly, October 29, 2026
Novo Nordisk obesity sales20% growth at constant exchange ratesQ3 2026 versus Q3 2025Novo Nordisk, November 4, 2026
Novo Nordisk injectable Wegovy sales13% decline at constant exchange ratesQ3 2026 versus Q3 2025Novo Nordisk, November 4, 2026

Buyer interpretation: product and channel mix matter more than a single market-growth headline. Novo’s obesity franchise growth alongside declining injectable Wegovy sales illustrates why a clinic should forecast oral, injectable, insured and self-pay activity separately. This is an inference from the reported results, not a forecast of any provider’s growth. Novo Nordisk results

Do not divide these revenues by prescription counts from another source to manufacture a “net price per patient.” The numerator and denominator may cover different channels, recognition periods and patient populations.

Explore the table row by row

A working view of the research

US GLP-1 spending across the broader category

Figure and observation period
Approximately $128 billion in 2025 — analyst calculation
Basis and limitation
ASHP reported approximately 14% of $915 billion in total prescription spending. Multiplication gives $128.1 billion; rounded because the underlying share is approximate. ASHP says direct-to-consumer sales are excluded. Includes more than obesity treatment.
Source and publication date
ASHP, April 30, 2026

Sources cited on this page

  1. news.ashp.org · Source 1 ↗https://news.ashp.org/news/ashp-news/2026/04/30/us-prescription-drug-spending-poised-to-cross-1-trillion-with-weight-loss-drugs
  2. academic.oup.com · Source 2 ↗https://academic.oup.com/ajhp/article/83/14/728/8662887
  3. iqvia.com · Source 3 ↗https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026
  4. lilly.gcs-web.com · Source 4 ↗https://lilly.gcs-web.com/node/55191/pdf
  5. sec.gov · Source 5 ↗https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm
Section sources →